Study information

Recruiting status

Study completed

Recruitment start





Clinical Trials Registration




DZHK Funding

EUR 1.286.691

Operative contact:
Main study centre - Farbod Sedaghat-Hamedani, MD

Studienzentren/Kontakt (PDF)

Translational registry for cardiomyopathies (TORCH-DZHK1)

Data is to be collected from some 2,300 patients with heart muscle damage (cardiomyopathy) whose condition was not caused by myocardial infarction, i.e. narrowing of the arteries. Instead this study will include patients who have suffered heart muscle damage for other reasons, for instance, as a result of genetic disposition or inflammatory processes. Diseases of the heart muscle have myriad causes and clinical manifestations. Therefore, the researchers intend to carry out detailed clinical examinations including taking small tissue samples from the heart by means of myocardial biopsy.

This is the first registry of its kind worldwide and by evaluating the data and biological material of a large number of patients over a long period of time researchers hope to find new evidence that will help them to identify the various causes of disease. Ultimately, earlier and more precise diagnosis of heart muscle diseases and better treatments could result.


Translational Registry for Cardiomyopathies (Torch) – Rationale and First Results. Seyler, C. et al. ESC heart failure, (2017).

All publications of this trial can be found here

Principal Investigators

Principal investigator: Hugo Katus (Heidelberg), Co-PI: Wolfgang Hoffmann (Greifswald)

Press releases and news

2,300 Patients in the DZHK Registry for Cardiomyopathies

The initial recruitment phase of the DZHK initiated study was successfully completed. The 2,300th...

The world’s largest patient registry on heart muscle disease has enrolled its 1,000th patient

Heidelberg/Greifswald/Berlin, 21 July 2016. The world’s largest patient registry on heart muscle...

Study recruitment is available in these cities

The map only displays recruitment locations within Germany.